Myositis study would have met the registrational primary endpoint; all these patients maintained their response off immunomodulators through latest follow-up, as long as 1.5 years First juvenile ...
Cabaletta didn't have any major announcements or any Securities and Exchange Commission (SEC) filings to make the stock rise. However, Guggenheim initiated coverage of the stock, with a price target ...
Cabaletta Bio Inc. (NASDAQ:CABA) is one of the top penny stocks to buy in investors’ stock portfolio. On May 14, Cabaletta Bio Inc. (NASDAQ:CABA) delivered positive clinical and translational data ...
Cabaletta (David Egan, whip up) beats Lady G (Hollie Doyle,right) in the bet365 Aphrodite Fillies’ Stakes Newbury 18.7.20 Edward Whitaker/Racing Post Cabaletta (David Egan, nearest) beats Lady G ...
Cabaletta Bio (NASDAQ:CABA) has observed the following analyst ratings within the last quarter: In the last 3 months, 7 analysts have offered 12-month price targets for Cabaletta Bio. The company has ...
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV® study presented today at ASGCT 2026 Annual Meeting along with initial ...
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases PHILADELPHIA, May 28, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc.
Cabaletta Bio, Inc. announced promising results from its ongoing RESET clinical trials for its investigational therapy rese-cel, focusing on autoimmune diseases. In the trials, notable outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results